Pharmacogenomics as a risk mitigation strategy for chemotherapeutic cardiotoxicity.

TitlePharmacogenomics as a risk mitigation strategy for chemotherapeutic cardiotoxicity.
Publication TypeJournal Article
Year of Publication2013
AuthorsJensen, Brian C., and Howard L. McLeod
JournalPharmacogenomics
Volume14
Issue2
Pagination205-13
Date Published2013 Jan
ISSN1744-8042
KeywordsAntineoplastic Agents, Cardiotoxins, Genetic Association Studies, Heart Failure, Humans, Pharmacogenetics, Risk
Abstract

Damage to the heart can result from both traditional chemotherapeutic agents, such as doxorubicin, and newer 'targeted' therapies, such as trastuzumab. This chemotherapeutic cardiotoxicity is potentially life-threatening and necessitates limiting or discontinuing an otherwise-effective cancer treatment. Clinical strategies focus on surveillance rather than prevention, although there are no specific therapies for this highly morbid adverse effect. Current models for prospectively predicting risk of chemotherapeutic cardiotoxicity are limited. Cardiotoxicity can occur idiosyncratically in patients without obvious demographic risk factors, suggesting a genetically determined susceptibility, and candidate-gene studies have identified a limited number of variants that increase risk. In this commentary we indicate a need for more powerful means to identify risk prospectively, and suggest that broad pharmacogenomic approaches may be fruitful.

DOI10.2217/pgs.12.205
Alternate JournalPharmacogenomics
Original PublicationPharmacogenomics as a risk mitigation strategy for chemotherapeutic cardiotoxicity.
PubMed ID23327580
PubMed Central IDPMC3582022
Grant ListK08 HL096836 / HL / NHLBI NIH HHS / United States
UL1 RR025747 / RR / NCRR NIH HHS / United States
P01CA142538 / CA / NCI NIH HHS / United States
P01 CA142538 / CA / NCI NIH HHS / United States
K08HL96836 / HL / NHLBI NIH HHS / United States
Project: